Sodium Carbonate → N-(2-Hydroxyethyl)-4'-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-4-biphenylsulfonamide

참여 물질

반응 단계

The title compound (4 mg, 2%) was prepared as a white solid from (4-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)boronic acid (98 mg, 0.4 mmol), 4-{[(4-bromophenyl)oxy]methyl}-1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]piperidine (prepared as in Example 24, Step 1, 152 mg, 0.4 mmol), Pd(PPh3)2Cl2 (100 mg, 0.14 mmol), 2M Na2CO3 (2 mL) and DME (2 mL) in a manner similar to Example 21, Step 3. 1H NMR (400 MHz, CDCl3): δ 7.90 (d, 2H, J=8.6 Hz), 7.68 (d, 2H, J=8.4 Hz), 7.54 (d, 2H, J=8.8 Hz), 6.98 (d, 2H, J=8.8 Hz), 4.84 (t, 1H, J=6.1 Hz), 4.26-4.16 (m, 2H), 3.89 (d, 2H, J=6.2 Hz), 3.76-3.70 (m, 2H), 3.20-3.07 (m, 4H), 2.98-2.85 (m, 1H), 2.38-2.18 (m, 1H), 2.10-2.04 (m, 1H), 2.03-1.93 (m, 2H), 1.57-1.40 (m, 2H), 1.29 (d, 6H, J=7.0 Hz); LRMS (ESI), m/z 501 (M+H).

출처 및 근거